• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients
 
  • Détails
Titre

Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients

Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Clinical & Experimental Immunology  
Auteur(s)
Cometta, A.
Auteure/Auteur
Baumgartner, J. D.
Auteure/Auteur
Glauser, M. P.
Auteure/Auteur
Liens vers les personnes
Cometta, Alain  
Baumgartner, Jean-Daniel  
Liens vers les unités
Maladies infectieuses  
ISSN
0009-9104
Statut éditorial
Publié
Date de publication
1994-07
Volume
97 Suppl 1
Première page
69
Dernière page/numéro d’article
72
Notes
Comparative Study
Journal Article
Review --- Old month value: Jul
Résumé
Infections remain the leading cause of death among patients admitted to intensive care units (ICU). Infections due to Gram-negative bacteria are both frequent and difficult to treat. The poor outcome of such infections has been attributed to the endotoxin. The high mortality rate related to Gram-negative sepsis has prompted the testing of new, adjunctive therapies to prevent and treat infections in critically ill patients. Immunotherapy or immunoprophylaxis have long been investigated in this context. Passive immunotherapy consists of the administration of immune plasma or serum, or standard or hyperimmune purified immune globulins. Several clinical studies using such preparations to treat critically ill patients are reviewed in this article. While two studies using hyperimmune plasma or serum appeared to be successful, two studies using hyperimmune globulin failed to show a beneficial effect in the treatment or the prevention of Gram-negative septic shock. Regarding the infusion of standard intravenous immune globulin (IVIG) two studies have demonstrated a substantial benefit in the prevention of severe infections; the reduction of nosocomial pneumonia recorded in both trials and the shortness of stay in ICU may also afford savings in hospital costs. The cost effectiveness of such prophylactic administration of IVIG is worthy of further investigation.
Sujets

Clinical Trials Criti...

PID Serval
serval:BIB_6C60880D886E
PMID
8033438
WOS
A1994NX80000013
Permalien
https://iris.unil.ch/handle/iris/200163
Date de création
2008-01-25T12:31:24.437Z
Date de création dans IRIS
2025-05-21T02:35:38Z
  • Copyright © 2024 UNIL
  • Informations légales